

#51696

Date: December 29, 2022 Subject: Gemini Therapeutics, Inc. - Reverse Split and Name/Symbol/CUSIP Change Option Symbol: GMTX New Symbol: IRON1 Date: 12/30/2022

Gemini Therapeutics, Inc. (GMTX) has announced a 1-for-10 reverse stock split, and a name, symbol, and CUSIP change, in conjunction with a reverse merger with Disc Medicine, Inc. As a result, each GMTX Common Share will be converted into the right to receive 0.10 (New) Disc Medicine, Inc. (IRON) Common Shares. The reverse stock split and underlying changes will become effective before the market open on December 30, 2022.

Additionally, under a CVR agreement, GMTX shareholders of record immediately prior to the effective time of the merger will receive one non-transferable Contingent Value Right (CVR) per share. The CVR represents a non-transferable contractual right to receive an additional payment to pre-merger shareholders of record on December 29, 2022, as described in the Proxy Statement/Prospectus dated December 2, 2022.

GMTX options will not be adjusted to call for the delivery of the CVRs.

Contract Adjustment	
Effective Date:	December 30, 2022
Option Symbol:	GMTX changes to IRON1
Contract Multiplier:	1
Strike Divisor:	1
New Multiplier:	100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)
New Deliverable Per Contract:	10 (New) Disc Medicine, Inc. (IRON) Common Shares
CUSIP:	IRON (New): 254604101
Pricing	

The underlying price for IRON1 will be determined as follows:

IRON1 = 0.10 (IRON)

## **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.